Anti-aging research has progressed rapidly over the last several years, with Google and even Amazon billionaire Jeff Bezos buying in. But the field’s latest investments will come from Apollo Health…
Johnson & Johnson has lost its global head, cell therapy platform and discovery. Tamas Oravecz took up the post at J&J’s Janssen earlier this year, only to leave to become chief scientific officer at…
Astellas Pharma is barreling forward on its gene therapy development following the $3 billion buyout of Audentes Therapeutics. The Japanese Pharma agreed to dole out up to $1.6 billion in biobucks for…
LabCorp and its CRO unit Covance, already striving toward a virtual trial platform, are taking another step into the next generation of clinical studies after penning a new pact with ConcertAI.
Apollo Health Ventures has positioned itself to place a fresh round of bets on age-related disease biotechs, raising $180 million to funnel into companies targeting everything from cardiovascular…
Curie Therapeutics launched with $75 million to tackle solid tumors using radiopharmaceuticals after 18 months of incubation. The new biotech is backed by three venture capital shops and is led by…
InVisionOS works with a hospital’s existing imaging picture archiving and communication system, or PACS, to produce 3D reconstructions from CT scans in the span of just a few seconds.
The so-called RECOVERY trial program undertaken in the U.K. since 2020 to assess how well treatments may or may not work against COVID was lauded as truly world-leading, but the country’s general…
Vertex in October gained plaudits and criticism in equal measure when it released data showing a single patient in a trial of its diabetes cell therapy stopped needing insulin; this time around, it’s…
Temperature-control technology maker Ember’s business runs hot and cold—literally.
